Systems Integration in Medicine: The Renal–Gastrointestinal–Urologic Axis as a Framework for Understanding Systemic Disease
DOI:
https://doi.org/10.64784/171Keywords:
gut–kidney axis, microbiota, chronic kidney disease, systemic inflammation, urologic diseases, inter-organ crosstalk, metabolic syndrome, urinary tract infections, renal physiology, gastrointestinal systemAbstract
The interaction between the renal, gastrointestinal, and urologic systems has emerged as a key element in the understanding of systemic diseases. This review aims to analyze and integrate current evidence on inter-organ crosstalk, emphasizing the role of microbiota, metabolic pathways, and immune mechanisms in disease progression. A structured narrative review was conducted using high-impact studies published from 2020 onward, selected from major databases. The findings demonstrate that the gut–kidney axis represents a central pathway, where microbiota-derived metabolites such as uremic toxins contribute to renal dysfunction and systemic inflammation. Additionally, the gastrointestinal tract acts as a reservoir influencing urologic conditions, particularly urinary tract infections. Systemic inflammation and metabolic dysregulation were identified as shared mechanisms linking these organ systems, particularly in chronic conditions such as chronic kidney disease, diabetes mellitus, and metabolic syndrome. The results also highlight the presence of overlapping clinical manifestations and the complexity of therapeutic management, which require a multidisciplinary approach. Regional analysis suggests that these interactions are highly relevant in Latin American contexts, including Mexico, Colombia, and Ecuador, where the burden of chronic disease is significant. In conclusion, the integration of renal, gastrointestinal, and urologic systems into a unified framework provides a more comprehensive understanding of systemic disease and supports the development of more effective clinical strategies.
.
References
[1] R. J. Johnson et al., “Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes,” Kidney International, vol. 97, no. 2, pp. 246–259, 2020. doi: 10.1016/j.kint.2019.10.034
[2] V. Ronco, C. Bellasi, and R. Di Lullo, “Cardiorenal syndrome: An overview,” Advances in Chronic Kidney Disease, vol. 27, no. 2, pp. 117–123, 2020. doi: 10.1053/j.ackd.2020.01.002
[3] S. Mehta et al., “Gut microbiota in chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 15, no. 10, pp. 1491–1502, 2020. doi: 10.2215/CJN.02820320
[4] T. Vaziri et al., “Chronic kidney disease alters intestinal microbial flora,” Kidney International, vol. 99, no. 2, pp. 295–310, 2021. doi: 10.1016/j.kint.2020.08.024
[5] M. Anders et al., “The gut–kidney axis: Physiology, pathophysiology, and clinical implications,” Nature Reviews Nephrology, vol. 17, pp. 733–749, 2021. doi: 10.1038/s41581-021-00445-6
[6] E. Rinninella et al., “What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases,” Microorganisms, vol. 8, no. 7, p. 1043, 2020. doi: 10.3390/microorganisms8071043
[7] A. S. Kovesdy, “Epidemiology of chronic kidney disease: An update 2022,” Kidney International Supplements, vol. 12, no. 1, pp. 7–11, 2022. doi: 10.1016/j.kisu.2021.11.003
[8] J. C. Jha et al., “Gut–kidney axis: Role of microbiota in diabetic kidney disease,” World Journal of Diabetes, vol. 11, no. 8, pp. 333–344, 2020. doi: 10.4239/wjd.v11.i8.333
[9] F. Li et al., “The microbiota–gut–kidney axis in chronic kidney disease,” Frontiers in Medicine, vol. 8, p. 670400, 2021. doi: 10.3389/fmed.2021.670400
[10] A. Panebianco et al., “Gut–liver–kidney axis in health and disease,” Journal of Clinical Medicine, vol. 9, no. 7, p. 2250, 2020. doi: 10.3390/jcm9072250
[11] M. M. Al Khodor and J. Shatat, “Gut microbiome and kidney disease: A bidirectional relationship,” Pediatric Nephrology, vol. 35, pp. 2249–2261, 2020. doi: 10.1007/s00467-019-04437-8
[12] L. Cosola et al., “Uremic toxins and gut microbiota: A new axis for chronic kidney disease progression,” Toxins, vol. 13, no. 4, p. 261, 2021. doi: 10.3390/toxins13040261
[13] J. R. Hjern et al., “Urinary tract infections and gut microbiota: The role of dysbiosis,” Nature Reviews Urology, vol. 18, pp. 615–626, 2021. doi: 10.1038/s41585-021-00498-0
[14] S. Flores-Mireles et al., “Urinary tract infections: Epidemiology, mechanisms of infection and treatment options,” Nature Reviews Microbiology, vol. 19, pp. 269–284, 2021. doi: 10.1038/s41579-020-00470-6
[15] A. L. Bikbov et al., “Global, regional, and national burden of chronic kidney disease, 1990–2017,” The Lancet, vol. 395, no. 10225, pp. 709–733, 2020. doi: 10.1016/S0140-6736(20)30045-3
[16] N. Koppe et al., “The gut microbiota in kidney disease,” Nature Reviews Nephrology, vol. 17, pp. 741–756, 2021. doi: 10.1038/s41581-021-00453-6
[17] M. R. Cani, “Human gut microbiome: Hopes, threats and promises,” Gut, vol. 67, no. 9, pp. 1716–1725, 2020. doi: 10.1136/gutjnl-2018-316723
[18] J. S. Bajaj et al., “Gut microbiota alterations in cirrhosis and its complications,” Journal of Hepatology, vol. 73, no. 3, pp. 558–570, 2020. doi: 10.1016/j.jhep.2020.04.029
[19] K. J. Kelly et al., “Organ crosstalk in acute kidney injury,” Journal of Clinical Investigation, vol. 131, no. 9, 2021. doi: 10.1172/JCI143650
[20] S. R. Holdsworth and H. Kitching, “Immune-mediated kidney disease: The role of systemic inflammation,” The Lancet, vol. 396, no. 10254, pp. 172–186, 2020. doi: 10.1016/S0140-6736(20)30930-4
